170 related articles for article (PubMed ID: 22293443)
1. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Palmer S; Boltz VF; Chow JY; Martinson NA; McIntyre JA; Gray GE; Hopley MJ; Mayers D; Robinson P; Hall DB; Maldarelli F; Coffin JM; Mellors JW;
Antivir Ther; 2012; 17(2):327-36. PubMed ID: 22293443
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
[TBL] [Abstract][Full Text] [Related]
3. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
McMahon DK; Zheng L; Hitti J; Chan ES; Halvas EK; Hong F; Kabanda J; Taulo F; Kumarasamy N; Bonhomme J; Wallis CL; Klingman KL; Hughes MD; Mellors JW
Clin Infect Dis; 2013 Apr; 56(7):1044-51. PubMed ID: 23300238
[TBL] [Abstract][Full Text] [Related]
4. Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Micek MA; Blanco AJ; Carlsson J; Beck IA; Dross S; Matunha L; Seidel K; Montoya P; Gantt S; Matediana E; Jamisse L; Gloyd S; Frenkel LM
J Infect Dis; 2012 Jun; 205(12):1811-5. PubMed ID: 22492850
[TBL] [Abstract][Full Text] [Related]
5. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S; Boltz V; Martinson N; Maldarelli F; Gray G; McIntyre J; Mellors J; Morris L; Coffin J
Proc Natl Acad Sci U S A; 2006 May; 103(18):7094-9. PubMed ID: 16641095
[TBL] [Abstract][Full Text] [Related]
6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
7. Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
Lallemant M; Le Coeur S; Sirirungsi W; Cressey TR; Ngo-Giang-Huong N; Traisathit P; Klinbuayaem V; Sabsanong P; Kanjanavikai P; Jourdain G; Mcintosh K; Koetsawang S;
AIDS; 2015 Nov; 29(18):2497-507. PubMed ID: 26372485
[TBL] [Abstract][Full Text] [Related]
8. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
[TBL] [Abstract][Full Text] [Related]
12. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Van Dyke RB; Ngo-Giang-Huong N; Shapiro DE; Frenkel L; Britto P; Roongpisuthipong A; Beck IA; Yuthavisuthi P; Prommas S; Puthanakit T; Achalapong J; Chotivanich N; Rasri W; Cressey TR; Maupin R; Mirochnick M; Jourdain G;
Clin Infect Dis; 2012 Jan; 54(2):285-93. PubMed ID: 22144539
[TBL] [Abstract][Full Text] [Related]
13. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission.
Mani M; Ramalingam VV; Lionel J; Christina SA; Sachithanandham J; Peedicayil A; Kannangai R
Indian J Med Microbiol; 2015; 33(2):225-30. PubMed ID: 25865972
[TBL] [Abstract][Full Text] [Related]
14. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
Muro EP; Fillekes Q; Kisanga ER; L'homme R; Aitken SC; Mariki G; Van der Ven AJ; Dolmans W; Schuurman R; Walker AS; Gibb DM; Burger DM
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):266-73. PubMed ID: 22134145
[TBL] [Abstract][Full Text] [Related]
15. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Church JD; Mwatha A; Bagenda D; Omer SB; Donnell D; Musoke P; Nakabiito C; Eure C; Bakaki P; Matovu F; Thigpen MC; Guay LA; McConnell M; Fowler MG; Jackson JB; Eshleman SH
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):673-7. PubMed ID: 19552593
[TBL] [Abstract][Full Text] [Related]
16. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF; Bao Y; Lockman S; Halvas EK; Kearney MF; McIntyre JA; Schooley RT; Hughes MD; Coffin JM; Mellors JW;
J Infect Dis; 2014 Mar; 209(5):703-10. PubMed ID: 24443547
[TBL] [Abstract][Full Text] [Related]
17. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
Hudelson SE; McConnell MS; Bagenda D; Piwowar-Manning E; Parsons TL; Nolan ML; Bakaki PM; Thigpen MC; Mubiru M; Fowler MG; Eshleman SH
AIDS; 2010 Feb; 24(4):557-61. PubMed ID: 20057308
[TBL] [Abstract][Full Text] [Related]
18. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Pérez H; Vignoles M; Laufer N; Gómez A; Coll P; Lottner J; Rolón M; Salomón H; Cahn P
Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
[TBL] [Abstract][Full Text] [Related]
19. Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
Fogel J; Hoover DR; Sun J; Mofenson LM; Fowler MG; Taylor AW; Kumwenda N; Taha TE; Eshleman SH
AIDS; 2011 Apr; 25(7):911-7. PubMed ID: 21487249
[TBL] [Abstract][Full Text] [Related]
20. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Moodley D; Moodley J; Coovadia H; Gray G; McIntyre J; Hofmyer J; Nikodem C; Hall D; Gigliotti M; Robinson P; Boshoff L; Sullivan JL;
J Infect Dis; 2003 Mar; 187(5):725-35. PubMed ID: 12599045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
